A better Vision = A better Future
Through Innovation and Technology
THERAMetrics is an international, full-service, technology-driven Contract Research & Development Organization (including cGMP IMP Services) providing technological services and solutions throughout the entire drug discovery & development cycle – from Preclinical to Market Access.
THERAMetrics works in collaboration with pharmaceutical, biotechnology and medical device Companies of all sizes to help accelerate the drug development process in the most profitable way.
Thanks to our concept “A better Vision = A better Future”, THERAMetrics is unique in its action plan. Because THERAMetrics believes that understanding its Customer's needs is the key success factor of a better Future, THERAMetrics opts for a wider angle of solutions to make its Customers reduce their TIME and COSTS.
THERAMetrics is a multi-functional group focused on four different clinical research segments:
1. Contract Research Organization: THERAMetrics’ high-quality and cost-effective full-service Contract Research Organization provides worldwide services such as international project management, regulatory support, study activation, monitoring, data management, medical coding, medical review, pharmacovigilance/drug safety, statistics and medical writing. To read more please click here.
2. Clinical Supply Services: THERAMetrics’ Clinical Supply Services (CSS) allows Customers to shorten their timelines and to reduce costs related to packaging, labeling and logistics of the Investigational Medicinal Product. To read more please click here.
3. Early Clinical Services: THERAMetrics has its own Clinical Research Units (CRU) for healthy volunteers, patients and special population offering an interdisciplinary team of experts who carries out safely and effectively Phase I and early Phases II and III in accordance to Good Clinical Practice (GCP) for a wide range of research fields. To read more please click here.
4. Drug Discovery: THERAMetrics provides an innovative approach to Clinical Research through its Drug Repositioning and Repurposing system (DRR 2.0) and integrated Clinical Development Services (iCDS). To read more please click here.
The Investigational Medicinal Products ("IMPs") include contract IMP manufacture and IMP logistics tailored to meet the specific requirements of Phase I-IV clinical trials.
The subsidiary Pierrel Research IMP Services ,approved by the European Medical Agency, provides high quality Investigational Medicinal Product (IMP) services for international clinical trials.
THERAMetrics has developed a valuable portfolio of patents and Orphan Drug Designations and is seeking opportunities for licensing out some of its projects and for joining partnerships for drug development.
DRR 2.0 is THERAMetrics' biomathematical platform for drug repositioning and repurposing through which it has obtained its patent portfolio.
With its innovative methodology, DRR 2.0 enables THERAMetrics to offer consultancy and partnerships to biotech and pharma companies for the development of new projects.
Therametrics provides full clinical research and scientific marketing services as well as of clinical trial services for research and development of new molecules and drug products to the pharmaceutical, biotechnology and healthcare industries.
The services provided include clinical trials application and management, e-Clinical Trial Technology, Pharmacovigilance and Drug Safety, Regulatory Services, Data Management & Statistical Evaluation and Medical Writing;
November 17, 2015
THERAMetrics holding AG (SIX:TMX) today provides an update on its restructuring plan announced last month
THERAMetrics holding AG (the "Company") today announces that it has concluded, over one month ahead of schedule, the restructuring of its German subsidiary as set forth in the Company’s global restructuring plan announced last month
November 13, 2015
THERAMetrics holding AG (SIX:TMX) today announces its financial results for the nine-month period ended September 30, 2015
THERAMetrics holding AG announces today its consolidated financial results for the nine-month period ended September 30, 2015
Stans, Switzerland, October 29, 2015
THERAMetrics holding AG (SIX:TMX) today announces the execution of a CHF 3.3 million convertible loan agreement
today announces that it has signed a CHF 3.3 million fully-subordinated convertible loan agreement with Fin Posillipo S.p.A and Bootes S.r.L..